[go: up one dir, main page]

PE20011270A1 - [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1) - Google Patents

[5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1)

Info

Publication number
PE20011270A1
PE20011270A1 PE2001000376A PE2001000376A PE20011270A1 PE 20011270 A1 PE20011270 A1 PE 20011270A1 PE 2001000376 A PE2001000376 A PE 2001000376A PE 2001000376 A PE2001000376 A PE 2001000376A PE 20011270 A1 PE20011270 A1 PE 20011270A1
Authority
PE
Peru
Prior art keywords
quinolon
guanidine
carbonyl
cyclopropil
pirazol
Prior art date
Application number
PE2001000376A
Other languages
Spanish (es)
Inventor
Angel Guzman-Perez
Eric David Cox
Weichao George Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20011270A1 publication Critical patent/PE20011270A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I [5-CICLOPROPIL-1-(2-QUINOLON-5-IL)-1H-PIRAZOL-4-CARBONIL]GUANIDINA CON LA CONDICION DE QUE EL COMPUESTO [5-CICLOPROPIL-1-(QUINOLON-5-IL)-1H-PIRAZOL-4-CARBONIL]GUANIDINA NO SE INCLUYA. LA DOSIS ES DE 0,01mg/kg/DIA A 50 mg/kg/DIA Y SE ADMINISTRA DE MODO PROFILACTICO, ANTES O DURANTE LA CIRUGIA Y EN LAS 24 HORAS SIGUIENTES A LA CIRUGIA. SE REFIERE TAMBIEN A UN COMPOSICION FARMACEUTICA. EL COMPUESTO DE FORMULA I ES UN INHIBIDOR DEL INTERCAMBIADOR DE SODIO-HIDROGENO TIPO 1 (NHE-1) Y ES UTIL PARA ES UTIL PARA REDUCIR LAS LESIONES TISULARES RESULTANTE DE LA ISQUEMIA O HIPOXIA EN DIFERENTES TEJIDOSREFERS TO A COMPOUND OF FORMULA I [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE WITH THE CONDITION THAT THE [5-CYCLOPROPYL-1- (QUINOLON -5-IL) -1H-PYRAZOLE-4-CARBONYL] GUANIDINE NOT INCLUDED. THE DOSE IS FROM 0.01mg / kg / DAY TO 50mg / kg / DAY AND IS ADMINISTERED PROPHYLACTICLY, BEFORE OR DURING SURGERY AND IN THE 24 HOURS AFTER SURGERY. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THE COMPOUND OF FORMULA I IS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1) AND IS USEFUL TO REDUCE TISSUE INJURIES RESULTING FROM ISCHEMIA OR HYPOXIA IN DIFFERENT TISSUES

PE2001000376A 2000-04-28 2001-04-26 [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1) PE20011270A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20043200P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
PE20011270A1 true PE20011270A1 (en) 2001-12-12

Family

ID=22741697

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000376A PE20011270A1 (en) 2000-04-28 2001-04-26 [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1)

Country Status (40)

Country Link
EP (1) EP1276737A1 (en)
JP (1) JP2003531900A (en)
KR (1) KR20020093079A (en)
CN (1) CN1225466C (en)
AP (1) AP2002002651A0 (en)
AR (1) AR028375A1 (en)
AU (1) AU2001235896A1 (en)
BG (1) BG107139A (en)
BR (1) BR0110268A (en)
CA (1) CA2407535A1 (en)
CO (1) CO5221125A1 (en)
CR (1) CR6797A (en)
CZ (1) CZ20023408A3 (en)
DZ (1) DZ3310A1 (en)
EA (1) EA004882B1 (en)
EE (1) EE200200615A (en)
GT (1) GT200100064A (en)
HN (1) HN2001000042A (en)
HR (1) HRP20020851A2 (en)
HU (1) HUP0300651A2 (en)
IL (1) IL152075A0 (en)
IS (2) IS6567A (en)
MA (1) MA26897A1 (en)
MX (1) MXPA02010600A (en)
MY (1) MY133842A (en)
NO (1) NO20025132L (en)
NZ (1) NZ521348A (en)
OA (1) OA12256A (en)
PA (1) PA8513301A1 (en)
PE (1) PE20011270A1 (en)
PL (1) PL357765A1 (en)
SK (1) SK14872002A3 (en)
SV (1) SV2002000418A (en)
TN (1) TNSN01065A1 (en)
TR (1) TR200202439T2 (en)
UA (1) UA73348C2 (en)
UY (1) UY26680A1 (en)
WO (1) WO2001083470A1 (en)
YU (1) YU79602A (en)
ZA (1) ZA200208605B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156220A0 (en) * 2001-01-31 2003-12-23 Pfizer Prod Inc Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
MXPA04004685A (en) * 2001-12-19 2004-08-12 Pfizer Prod Inc Methods for preparing sodium-hydrogen exchanger type-1 inhibitors.
EP1499317A1 (en) * 2002-05-02 2005-01-26 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors
FR2840302B1 (en) * 2002-06-03 2004-07-16 Aventis Pharma Sa ISOINDOLONE DERIVATIVES, PREPARATION METHOD AND INTERMEDIARY THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
ES2220185B1 (en) * 2002-07-16 2006-04-01 Consejo Sup. De Investig. Cientificas NEW INHIBITOR PEPTIDE OF THE NA + / H + EXCHANGER (PINHE), AND ITS APPLICATIONS.
JP2006517976A (en) * 2003-02-14 2006-08-03 スミスクライン・ビーチャム・コーポレイション New compounds
RU2518741C1 (en) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" MEDICATION, INHIBITING Na+/H+-EXCHANGE, AND HALOGENIDES OF 1-DIALKYLAMINOETHYL-3-[SUBSTITUTED(DISUBSTITUTED)PHENACYL]-2-AMINOBENZIMIDAZOLIUM

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030078886A (en) * 1998-02-27 2003-10-08 화이자 프로덕츠 인크. N-[(Substituted Five-Membered Triaza Diunsaturated Ring)Carbonyl] Guanidine Derivatives for the Treatment of Ischemia

Also Published As

Publication number Publication date
NO20025132D0 (en) 2002-10-25
MXPA02010600A (en) 2003-03-10
CO5221125A1 (en) 2002-11-28
IS6567A (en) 2002-09-24
IL152075A0 (en) 2003-05-29
EA004882B1 (en) 2004-08-26
PL357765A1 (en) 2004-07-26
GT200100064A (en) 2002-03-22
CA2407535A1 (en) 2001-11-08
WO2001083470A1 (en) 2001-11-08
CR6797A (en) 2004-05-17
CN1426404A (en) 2003-06-25
JP2003531900A (en) 2003-10-28
TNSN01065A1 (en) 2005-11-10
MY133842A (en) 2007-11-30
NO20025132L (en) 2002-12-12
AR028375A1 (en) 2003-05-07
CZ20023408A3 (en) 2004-01-14
UY26680A1 (en) 2001-12-28
HN2001000042A (en) 2001-07-09
ZA200208605B (en) 2003-10-24
CN1225466C (en) 2005-11-02
EA200201023A1 (en) 2003-02-27
UA73348C2 (en) 2005-07-15
AP2002002651A0 (en) 2002-12-31
OA12256A (en) 2003-11-06
AU2001235896A1 (en) 2001-11-12
MA26897A1 (en) 2004-12-20
YU79602A (en) 2006-05-25
HUP0300651A2 (en) 2003-07-28
IS6588A (en) 2002-10-21
SV2002000418A (en) 2002-07-03
EE200200615A (en) 2004-04-15
NZ521348A (en) 2004-09-24
EP1276737A1 (en) 2003-01-22
TR200202439T2 (en) 2003-02-21
KR20020093079A (en) 2002-12-12
SK14872002A3 (en) 2004-03-02
DZ3310A1 (en) 2001-11-07
BR0110268A (en) 2003-12-30
HRP20020851A2 (en) 2005-02-28
PA8513301A1 (en) 2003-09-05
BG107139A (en) 2003-07-31

Similar Documents

Publication Publication Date Title
MXPA03005464A (en) Antiviral agents.
IS8502A (en) Azate cyclic heterocycles as cannabinoid receptor antagonists
CU23105A3 (en) NOVEDOUS DERIVATIVES OF AMINODICARBOXILIC ACID WITH PHARMACEUTICAL PROPERTIES
PA8593001A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
BRPI0313942B8 (en) benzimidazole derivatives useful as antiproliferative agents, their preparation processes, pharmaceutical composition comprising the same and uses of said compounds in the preparation of pharmaceutical compositions
GT200100137A (en) PRO-DRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES.
PA8591701A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
PL402388A1 (en) Pyrimidine derivative, its use and pharmaceutical composition containing it
ECSP024393A (en) SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH
ECSP077185A (en) PIRIDINE DERIVATIVES
MY123310A (en) Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
UY27872A1 (en) CASPASA INHIBITORS AND USES OF THE SAME.
AR036248A1 (en) DERIVATIVES OF 2H-PIRIDAZIN-3-ONA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND A PROCESS FOR THE PREPARATION OF SUCH DERIVATIVES AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
ECSP045138A (en) 4-Phenyl-tetrahydro-isoquinolines substituted, procedure for its preparation, its use as a medicine and medicine containing them
MXPA05006889A (en) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
BR0012951A (en) Selective retinoid agonists
PE20011270A1 (en) [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1)
ES2060173T3 (en) LISOLECITINE DERIVATIVES FOR THE TREATMENT OF AUTOIMMUNOLOGICAL DISEASES.
AR058180A1 (en) INDENO DERIVATIVES, ITS PREPARATION AND ITS USE AS MEDICATIONS
TR200102008T2 (en) Use of pyridine derivatives for prophylaxis and treatment of cerebral ischemia.
BR0311363A (en) Immediate release pharmaceutical formulation, use thereof, and method for treating a cardiovascular disorder in a patient
CR7931A (en) 4 - [(2,4-DICLORO-5-METROXIFENIL) AMINO] -6-ALKOXI-3- CHINOLINCARBONITRILS FOR THE TREATMENT OF ISCHEMICAL INJURIES
BRPI9509819B8 (en) enterokinetic benzamide and pharmaceutical composition comprising the same
PA8450901A1 (en) Erythromycin derivatives
PA8474401A1 (en) 3-KETO TRICYCLIC DERIVATIVES OF 6-0-METHYLERITHROMYCIN

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed